A type of brain cancer once widely described as “a death sentence” has shown an unexpected shift.
In a matter of days, tumors that would normally continue growing began shrinking, surprising even the surgeons involved in the treatment. Three patients with recurrent glioblastoma, who had exhausted standard options, chose to try an experimental version of CAR-T therapy. What followed left both MRI scans—and the medical team—stunned.
In March 2024, doctors at Mass General Brigham tested a new variation of CAR-T therapy on three people with recurrent glioblastoma, one of the most aggressive brain cancers. Rather than using the standard method, researchers paired CAR-T cells with targeted antibodies to improve how precisely the immune system could attack the tumor inside the brain.
The therapy was delivered directly into the cerebrospinal fluid surrounding the brain and spinal cord, allowing the engineered immune cells to interact with the tumor more directly.
The results surprised the team. One patient’s tumor shrank by 18.5% within two days and later reduced by more than 60% over ten weeks. Another patient also showed rapid tumor regression, while a third displayed clear MRI changes within just five days.
Researchers emphasize these are very early findings based on only three patients, not proof of a cure. Still, for a cancer that has long carried such a grim outlook, the trial offers something rarely seen in glioblastoma research: early evidence that the disease may have a vulnerability after all.